Compare GSK plc (GSK) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Levi Strauss & Co. — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Levi Strauss & Co. trades at $19.01 (market cap $7.31B). The key difference: GSK plc is far larger — about 12.6× Levi Strauss & Co.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Levi Strauss & Co. for 70 Days on average.
| GSK | LEVI | |
|---|---|---|
Market Cap | $91.88B | $7.31B |
Volume | 7,730,529 | 13,683,095 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $25.53 |
52-Week Low | $43.24 | $17.92 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $111.88B | $8.86B |
Dividend Yield | 3.9% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Levi Strauss (LEVI) trades at $19.51, down 4.97% today, amid a bearish technical signal but strong fundamentals. The company has consistently beaten earnings estimates, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.84 and P/S of 1.15, while profitability remains robust with a net income margin of 9.66% and ROE of 29.31%. Recent news highlights a new CFO appointment and positive analyst sentiment on denim demand.
The outlook is positive given earnings momentum and analyst consensus, with a price target of $27.80 implying significant upside. Risks include competitive pressures and recent cybersecurity incidents, but strong cash flow and dividend payments support shareholder value. Wall Street sentiment is bullish with 79% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
